Ozempic

2024 - 3 - 4

Irish Women Embrace Ozempic for Weight Loss - What You Need to Know

alcohol dependence - clinical trials - diabetes treatment - kidney disease - Novo Nordisk - Ozempic - semaglutide - Wegovy - weight loss

Join the trend and discover how Irish women are turning to Ozempic for weight loss in surprising ways!

In a bid to tackle excess weight, Irish women are increasingly turning to drugs like Ozempic for weight loss. However, concerns are emerging about the impact of these medications on pregnant individuals. The active ingredient in popular weight loss drugs like Wegovy and Ozempic, semaglutide, is being studied for unexpected benefits, potentially extending beyond weight loss to treat alcohol addiction. Over 25,500 Irish people now receive Ozempic for free through HSE schemes, although its use is primarily aimed at managing diabetes rather than weight loss.

Studies are underway to explore the effects of Ozempic on pregnant individuals and the risks it may pose to a developing fetus. The potential of semaglutide, found in drugs like Ozempic, to aid in alcohol addiction treatment is a surprising but promising discovery. With a considerable number of Irish individuals benefiting from Ozempic through healthcare schemes, the drug's impact on weight loss and its broader implications continue to spark interest and debate.

Post cover
Image courtesy of "The New York Times"

Women Turn to Drugs Like Ozempic for Weight Loss Before ... (The New York Times)

Excess weight may increase the risk of miscarriage and pregnancy complications. But little is known about the impact of drugs like Ozempic on a fetus.

Post cover
Image courtesy of "CBS News"

Unexpected side effect from popular weight loss drugs studied for ... (CBS News)

Several clinical trials are underway to see if semaglutide, the active ingredient in weight loss drugs like Wegovy and Ozempic, can also help treat alcohol ...

Post cover
Image courtesy of "Independent.ie"

More than 25000 Irish people now receiving weight-loss jab ... (Independent.ie)

More than 25500 people are now receiving the weight-loss drug Ozempic for free through HSE schemes, but only to treat diabetes.

Post cover
Image courtesy of "Fortune"

Novo Nordisk's Wegovy and Ozempic boom saved Denmark's GDP ... (Fortune)

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. โ€œIt does not look like Novo Nordisk is slowing down, ...

Post cover
Image courtesy of "The Wall Street Journal"

Novo Nordisk Says Ozempic Drug Cuts Risk of Kidney Problems (The Wall Street Journal)

Ozempic was originally developed to treat diabetes, but its use for weight loss has rapidly grown.

Post cover
Image courtesy of "STAT"

Novo Nordisk's diabetes drug Ozempic cuts risk of kidney disease ... (STAT)

A Novo Nordisk study showed that its diabetes drug Ozempic lowered the risk that patients with kidney disease would see progression.

Post cover
Image courtesy of "Morningstar.com"

Novo Nordisk says Ozempic reduced risk of kidney problems by 24 ... (Morningstar.com)

The trial compared injectable semaglutide, which the company markets as Ozempic, with placebo to evaluate its efficacy in treating people with Type 2 diabetes ...

Post cover
Image courtesy of "pharmaphorum"

Novo Nordisk looks set to add another string to Ozempic bow (pharmaphorum)

Novo Nordisk's Ozempic achieved a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW ...

Post cover
Image courtesy of "Proactive Investors UK"

Novo Nordisk reveals positive Ozempic kidney results (Proactive Investors UK)

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under.

Post cover
Image courtesy of "TipRanks"

Novo Nordisk's (NYSE:NVO) Ozempic Shows Promise in Lowering ... (TipRanks)

Novo Nordisk's (NYSE:NVO) Ozempic lowered the risk of kidney disease progression in patients with type-2 diabetes and chronic kidney disease by nearly 24%.

Explore the last week